Poster #1980

MP0250 COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS PREVIOULSY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS

Stefan Knop¹, Hartmut Goldschmidt², Marc. S. Raab², Monika Szarejko³, Artur Jurczyszyn⁴, Jan Duerig⁵, Sara Bringhen⁶, Barbara Gamberi⁷, Angelo Vacca⁸, Jorge Acosta⁹, Guy Lemaillet⁹, Cédric Cortijo⁹, Sudhir Bansod⁹, Norbert Grzasko¹⁰.

¹Department of Medicine II, University Hospital Wurzburg, Germany, ²Department of Hematology, And Rheumatology, and Rheumatology, and Rheumatology, Heidelberg University Hospital, Clinical Department of Hematology, Krakow, Poland, ⁵Department of Hematology, University Hospital Essen, Germany, ⁶Department of Oncology and Hematology, Clinical trials in onco-hematology, Clinical trials in onco-hematology Complex Operative Unit, Senior Hospital Santa Maria Nuova, Reggio Emilia, Italy, ⁸Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, University of Bari Medical School, Bari, Italy, ⁹Molecular Partners AG, Zürich, Switzerland, ¹⁰Department of Hematology, Centre of Oncology of the Lublin Region, Poland.

MP0250 Mechanism of Action

MP0250 is a first-in-class selective tri-specific multi-DARPin® drug candidate neutralizing VEGF-A and HGF as well as binding to human serum albumin to increase its plasma half-life (Figure 1). Preclinical studies have shown that MP0250 enhances sensitivity of Multiple Myeloma (MM) cells to bortezomib, inhibits tumour growth and reduces bone destruction¹. In this clinical phase 2 trial we are investigating the safety, tolerability and efficacy of the

combination of MP0250 plus bortezomib and dexamethasone (dex) in patients (pts) with relapsed/refractory (RR) MM previously exposed to proteasome inhibitors (PI) and immunomodulatory drugs (IMiD).




Figure 1. Model of MP0250 with binding surfaces in colour. DARPin® is a registered trademark owned by Molecular Partners AG

MP0250-CP201 Study Design

This study is a Phase II open-label, single-arm, multicenter trial of MP0250 plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. A dose-escalation phase (part 1) consisting of two cohorts will define a safe dose of the combination of MP0250 plus bortezomib + dex followed by a dose-expansion phase (part 2).

This trial is recruiting adults ≥18 years of age with RRMM who have progressed after at least two prior treatment regimens including bortezomib and an IMiD. A dose-escalation phase (part 1) consisting of two cohorts will define a safe dose of the combination of MP0250 plus bortezomib + dex followed by a dose-expansion phase (part 2).

Enrolled patients receive iv MP0250 on day 1 + subcutaneous bortezomib 1.3 mg/m² on days 1, 4, 8, 11, oral dexamethasone (dex) 20 mg on days 1-2, 4-5, 8-9, 11-12 of each 21-day cycle. Up to 40 patients will be enrolled. Patients will receive treatment until there is documented disease progression or unacceptable toxicity.

Study MP0250-CP201 (NCT03136653) is being conducted at 9 centres in three European countries (Germany, Italy and Poland).

Methods

Eligible patients were aged \geq 18 years with an Eastern Cooperative Oncology Group performance status of \leq 1 and documented diagnosis of RRMM with measurable disease by serum M protein ≥ 0.5 g/dL or urine M protein ≥ 200 mg/24 h.

Patients with a history of the previously have peripheral neuropathy ≥ 2 or active congestive heart failure, myocardial infarction within 6 months prior to screening and/or uncontrolled hypertension are ineligible.

The primary endpoint is overall response rate (ORR) per International Myeloma Working Group Uniform Response criteria. Secondary endpoints include safety, immunogenicity, progression free survival, and duration of response. Exploratory endpoints include overall survival and pharmacokinetics. The safety analysis set is defined as patients who have received at least ' dose of the combination of MP0250 plus bortezomib + dexamethasone.

Data cut off was 02 November 2018. 8 pts have been treated in cohort 1 (8 mg/Kg q3w) and 3 pts in cohort 2 (12 mg/Kg q3w). Part 2, is currently open and recruiting patients to receive 8 mg/kg q3w (the recommend Part 2 dose). At cut-off date, two patients have enrolled in part 2.

Table 1. Patient demography and baseline characteristics

Demographics	Part 1 Esc	Part 2 Expansion		
	Cohort 1 (8 mg/Kg) n = 8	Cohort 2 (12 mg/Kg) n = 3	8 mg/Kg n = 2 62	
Median age (y)	57.75	55.66		
Gender (F/M)	4 / 4	2/1	2/0	
ECOG, n (%) 0	4	2	1	
1	4	1	1	
B2-microglobulin (mg/L) Median (range)	3.65 (2.2-6.9)	3.36 (2.5-5.1)	2.35 (1.6 – 3.1)	
Haemoglobin (g/L) Median (range)	120.5 (95-143)	121.66 (101-134)	117 (97-137)	
Platelets, x10 ⁹ /L Median (range)	181.1 (72-327)	153.6 (111-219)	245.5 (146-345)	
ANC, x10 ⁹ /L Median (range)	2.68 (1.3-4.4)	3.03 (2.3-3.8)	2 (1.3-2.7	
Median prior lines of treatment (range)	3.25 (2-5)	3.5 (3-5)	4.5 (3-6)	
Time from initial diagnosis (y) Median (range)	4.7 (1.3-10)	5.5 (2.5-9)	10 (8-12)	
PI Refractory , n (%)	4 (50%)	3 (100%)	1 (50%)	
Prior SCT, n (%)	7 (87.5%)	3 (100%)	2 (100%)	

Table 2. Patient Disposition

	Part 1: Dos	Part 2: Expansion	
	Cohort 1: 8 mg/Kg (n =8)	Cohort 2: 12 mg/Kg (n = 3)	8 mg/Kg (n = 2)
On treatment, n (%)	1	0	2
Discontinued, n (%)			
PD	4	2	0
Consent withdrawn	1	0	0
AE	2	1	0
Death	0	0	0

Most common adverse events during treatment							
Adverse Event	Part 1: Dose escalation						
	Cohort 1: 8 mg/Kg (n=8)		Cohort 2: 12 mg/Kg (n=3)				
	Any Grade	Grade \geq 3	Any Grade	Grade ≥ 3			
Hematologic adverse events							
Neutropenia	-	-	3 AE (1 pt.)	2 AEs (1 pt.)			
Thrombocytopenia	4 AEs (3 pts.)	1 AE (1 pt.)	12 AEs (3 pts.)	8 AEs (3 pts.)			
Anaemia	-		8 AEs (2 pts.)	4 AEs (2 pts.)			
Non-hematologic adverse events							
Epistaxis	-	-	5 AEs (1 pt.)	1 AE (1 pt.)*			
Peripheral Sensory Neuropathy	2 AE (1 pt.)	-	1 AE (1 pt.)	-			
Hypertension	5 AEs (5 pts.)	3 AE (3 pt.)	3 AEs (3 pt.)	1 AE (1 pt.)			
Proteinuria	1 AE (1 pt.)	1 AE (1 pt.)	2 AEs (2 pt.)	1 AE (1 pt.)**			
Nausea	1 AE (1 pt.)	1 AE (1 pt.)	3 AEs (1 pt.)	-			
Respiratory tract infection	1 AE (1 pt.)	1 AE (1 pt.)	1 AE (1 pt.)	-			
ALT elevation	2 AEs (1 pt.)	1 AE (1 pt.)	-	-			
AST elevation	1 AE (1 pt.)	-	-	-			
GGT elevation	1 AE (1 pt.)	1 AE (1 pt.)	-	-			
Diarrhoea	_	-	1 AE (1 pt.)	-			

Patients and treatments

Pharmacokinetics and Immunogenicity

Figure 2. Concentration x time profile for MP0250 in cohort 1 patients (\geq 3 doses) [n = 7]





Table 3. Treatment Emergent Adverse Event reported (N=11)

• No AEs reported in 2 patients enrolled in Part 2 Expansion phase (8 mg/kg) at data cut-off. • The most frequent drug-related grade \geq 3 AEs: hypertension in 4 pts, thrombocytopenia in 4 pts, proteinuria in 2 pts and transient liver enzyme elevation in 1 patient

• 2 Dose Limiting Toxicity events were observed in cohort 2 (grade 3 epistaxis*, grade 3 proteinuria**), enrollment stopped at 12 mg/Kg and the next lower dose level (8 mg/kg) is considered the MTD.

Figure 3. Concentration x time profile for MP0250 in cohort 2 patients [n = 3]



- is proportional to dose.
- with single agent administration of MP0250
- and no impact on PK profile or exposure to MP0250.

• Repeated MP0250 dosing led to sustained drug exposure throughout the treatment periods analysed, the longest to-date being 12 months; MP0250 exposure for cohort 1 and cohort 2

• MP0250 in combination with bortezomib and dexamethasone has a half-life of ca. 11 days (range: 6-17 days) and shows only slight accumulation upon repeated dosing (factor 1.4-3.1 based on C_{min}, C_{max} and AUC); pharmacokinetics are similar to those previously observed


• All 11 patients in the dose-escalation portion were assessed for anti-drug antibody (ADA) formation; 2 patients were found to be ADA positive with very low and stable titer (range 1-4)

Efficacy

All 11 patients in the dose escalation portion were evaluable for tumour response (Fig.4). The ORR (better than or equal to PR) for all treated patients was 45.5%. Figure 4. Response outcomes

ORR 45.45% Cohort 1 8 mg/Kg All patients PD

Figure 5. Treatment duration



response. One patient has been on treatment longer than 12 months and achieved VGPR (Fig.5). Duration of follow-up for Part 2 patients is too short.

Conclusions

Data from cohort 1 (8 mg/Kg q3w) suggest that MP0250 can be safely combined with bortezomib and dex in patients with relapsed and refractory MM.

While the number of patients treated is still small, early responses observed in bortezomibrefractory patients are promising and justify further evaluation of MP0250 therapy in combination with bortezomib plus dex in RRMM

Acknowledgment

We thank the patients and families who contributed to this study, as well as the study investigators, nurses and clinical research personnel from the study centres across Europe. This study is sponsored by Molecular Partners AG.

References

1) Fiedler U, Ekawardhani S, Cornelius A, et al. Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin protein MP0250: a preclinical study. Oncotarget. 2017;8(58):98371-83.